Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY save search
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-09-08 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -1.67%
H: 10.61%
C: 10.19%
positive results study
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-11-04 (Crawled : 18:00) - biospace.com/
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 0.06%
H: 0.26%
C: 0.19%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.24%
H: 7.69%
C: 7.59%
kidney
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.59 -3.04% -3.26% 130K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Published: 2022-06-14 (Crawled : 07:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.77%
H: 6.48%
C: 3.71%
treatment fda approval
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
Published: 2022-02-10 (Crawled : 13:30) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
IONS | $42.45 1.46% 1.45% 730K
|
Health Technology
|
| O: 0.7%
H: 3.82%
C: 0.78%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.66%
H: 6.03%
C: 1.83%
als financial results report results
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published: 2023-08-03 (Crawled : 11:00) - globenewswire.com
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
AGIO | $31.67 -0.44% -0.44% 640K
|
Health Technology
|
| O: -2.4%
H: 5.98%
C: 2.81%
license treatment potential agreement
Alnylam Announces New Advances in ATTR Amyloidosis Program
Published: 2021-05-11 (Crawled : 12:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -1.69%
H: 5.46%
C: 4.71%
program
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -1.53%
H: 5.32%
C: 5.2%
conference financial results
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
RNAi Roundtable: Givosiran, for the Treatment of Acute Hepatic Porphyria
Published: 2021-08-04 (Crawled : 18:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.88%
H: 5.21%
C: 3.5%
treatment hepatitis
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Published: 2021-06-30 (Crawled : 12:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.28%
H: 5.14%
C: 2.48%
phase 2 hypertension
RNAi Roundtable: Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension
Published: 2021-06-30 (Crawled : 15:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.28%
H: 5.14%
C: 2.48%
treatment hypertension
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
Published: 2022-08-24 (Crawled : 21:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.0%
H: 3.6%
C: 1.66%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 1.26%
H: 3.73%
C: 0.62%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.44%
H: 2.9%
C: 1.45%
ADAP | $1.08 -5.26% -5.07% 790K
|
Health Technology
|
| O: 0.46%
H: 5.04%
C: 1.83%
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-01-07 (Crawled : 15:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 5.35%
H: 4.77%
C: 4.33%
positive results phase 3 topline
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
Published: 2021-06-03 (Crawled : 22:00) - biospace.com/
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -0.05%
H: 1.1%
C: 1.1%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 1.86%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.72%
H: 4.77%
C: 3.86%
conference
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-04-13 (Crawled : 18:40) - fda.gov
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 0.03%
H: 0.56%
C: 0.0%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.03%
H: 1.03%
C: 0.22%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -1.85%
H: 0.42%
C: -0.3%
YMAB | $15.29 -0.33% -0.52% 160K
|
Health Technology
|
| O: 0.55%
H: 5.75%
C: 4.16%
VSTM | $9.31 -3.12% -3.44% 79K
|
Health Technology
|
| O: -1.85%
H: 2.64%
C: 1.13%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.56%
H: 0.18%
C: -0.4%
RIGL | $1.125 -1.32% -1.33% 6.5M
|
Health Technology
|
| O: -1.66%
H: 9.58%
C: 5.07%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.2%
H: 1.83%
C: 0.66%
KPTI | $1.09 0.91% 1.2M
|
Health Technology
|
| O: 0.89%
H: 5.1%
C: 0.1%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: 0.0%
H: 3.18%
C: 1.93%
ILMN | $122.87 -1.28% -1.4% 330
|
Health Technology
|
| O: 0.87%
H: 0.47%
C: -2.11%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.38%
H: 4.2%
C: 3.09%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 0.18%
H: 3.17%
C: 0.24%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.0%
H: 4.56%
C: 1.79%
BPMC | $92.26 -0.03% 0.02% 590K
|
Health Technology
|
| O: 0.37%
H: 6.32%
C: 3.68%
BGNE | $144.12 3.69% 3.48% 150
|
Health Technology
|
| O: 0.24%
H: 2.16%
C: -0.12%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.15%
H: 2.63%
C: -0.15%
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
|
| O: 0.01%
H: 0.61%
C: -0.14%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.86%
H: 2.16%
C: 0.66%
AGIO | $31.67 -0.44% -0.44% 640K
|
Health Technology
|
| O: 0.73%
H: 4.5%
C: 1.75%
cancer approval
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2021-11-19 (Crawled : 12:30) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -2.38%
H: 4.35%
C: 3.59%
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Published: 2021-08-09 (Crawled : 12:15) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.37%
H: 4.18%
C: 3.46%
media phase 3 cardio enroll
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.